Adamis Pharmaceuticals Corp (ADMP): David J. Marguglio , SR. VP of Corporate Devel. of Adamis Pharmaceuticals Corp sold 700 shares on Jun 2, 2016. The Insider selling transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were sold at $9.00 per share for a total value of $6,301.05 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, David J. Marguglio (SR VP OF CORPORATE DEVELOPMENT) sold 4,000 shares at $8.09 per share price.On Aug 17, 2015, Richard C Williams (director) purchased 9,800 shares at $3.26 per share price.Also, On Aug 17, 2015, Robert B Rothermel (director) purchased 7,000 shares at $3.35 per share price.
Adamis Pharmaceuticals Corp (ADMP) witnessed a volatile trading activity on Friday Jun 3, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $8.85 and reached the intraday high at $8.9399. The bulls started the profit booking and pushed the shares to intraday low of $8.5235. The trading session was marked by a volume range of 2,83,664 shares exchanging hands. The 52-week high of the shares is $10.98 and the 52-week low is $3.05. The market cap of the company stands at $134 M and there are 1,51,03,744 shares in public circulation.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is developing various products in the allergy and respiratory markets The Company’s product portfolio includes specialty pharmaceutical products such as Epinephrine pre-filled syringe (PFS) APC-5000 dry powder inhaler (DPI) APC-1000 APC-2000 and APC-3000 and biotechnology products such as TeloB-VAX (vaccine) APC-100 APC-200 and APC-300. The Company’s product candidates for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are APC-5000 DPI and APC-1000. The Company’s other product candidates in its allergy and respiratory product pipeline include APC-1000 APC-3000 and APC-2000. The Company’s drug candidates for the treatment of prostate cancer are APC-100 APC-200 and APC-300. The Company also has a microbicide product candidate named Savvy (C31G). The Company’s product candidate for the treatment of anaphylaxis is Epinephrine PFS.